Omacycline versus moxifloxacin in the treatment of community-acquired pneumonia in elderly patients
Objective To explore the efficacy and safety of omadacycline versus moxifloxacin in the treatment of community-acquired pneumonia(CAP)in elderly patients.Methods By collecting and analyzing the medical records of 62 elderly patients with community-acquired pneumonia(CAP)admitted to Third People's Hospital of Kunming from March 2023 to September 2023,the patients were divided into an omadacycline treatment group(n=31)and a moxifloxacin treatment group(n=31)based on their medication regimen.The clinical efficacy and occurrence of adverse reactions in both groups were observed,and the data were processed by SPSS23.0 statistical software.Results The clinical effective rate in the omadacycline and moxifloxacin group was 93.55％and 96.77％,respectively,with no statistically significant difference(P＞0.05).The adverse reaction rate was slightly higher in the omadacycline group compared to the moxifloxacin group,and the difference was not statistically significant(P＞0.05).There were statistically significant differences in K+,hemoglobin,urea nitrogen and total protein between the two groups after treatment(P＜0.05),and the patients in both groups exhibited good tolerability during treatment.Conclusions Omadacycline demonstrates non-inferior efficacy to moxifloxacin in the treatment of CAP in elderly patients,with good safety profiles,offering a novel therapeutic option for elderly patients with community-acquired pneumonia.
万方数据
维普
